You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | -7,908.0% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -2.3 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 243.3 | n/a |
Price / Book value | 5.7 |
Latest | Forecast | |
---|---|---|
Revenue | 212.5% | n/a |
PBT | 0.0% | n/a |
EPS | 0.0% | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2020-08-31 | n/a | -0.17 | -2.85p | -29.8 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 0.00 | -4.80 | -7.87p | -21.0 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 0.02 | -18.12 | -29.70p | -1.7 | 0.0 | n/a | n/a | 0.0% |
2023-12-31 | 0.08 | -7.52 | -11.50p | -10.0 | 0.0 | n/a | n/a | 0.0% |
Celadon Pharmaceuticals finance chief to step down Sharecast News | 30 Sep |
---|---|
Celadon inks partnership with Denmark's Valeos Sharecast News | 11 Sep |
Celadon confident in seeing through funding challenges Sharecast News | 23 Aug |
New Sales Contract with a Healthcare Company | 02-Oct-24 07:01 |
---|---|
Departure of Chief Financial Officer | 30-Sep-24 07:06 |
Interim Results | 30-Sep-24 07:02 |
Admission of Shares and Total Voting Rights | 17-Sep-24 09:29 |
Equity Fundraise and Update on Financial Position | 11-Sep-24 07:05 |